* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
To the reaction flask, 1.35 g of sodium hydroxide and 3.3 ml of water were added, and the mixture was cooled to 25 °C or lower, and 1.35 g of the starting material (Compound 2) was slowly added with stirring. The mixture was further stirred for 1.5 to 2 hours, and then the reaction solution (2 × 27ml), water phase filtration. The filtrate was stirred with 2M hydrochloric acid to adjust the pH to 3.0, and the mixture was stirred for 2 hours. The product was washed with distilled water and the solid was dried under vacuum at 80 °C for 10 hours to give 0.96 g of product, 80percent yield and 99.5percent HPLC purity.
80.6%
at 20℃; for 2 h;
340.0 g of N-[[5-[N-(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)-methyl]-N-methyl]Amino-2-thiophenecarbonyl]-L-glutamic acid diethyl ester was added in portions to a 3N sodium hydroxide solution (6500 ml) and the reaction was stirred at room temperature for 2 hours. TLC monitored the progress of the reaction. After the reaction was completed, the pH was adjusted to 3 to 4 with 3N hydrochloric acid, the crystals were further stirred for 1 hour, and suction filtered to give a yellow solid. Recrystallization from methanol-water (4:1) gave 244.2 g of a pale yellow solid, namely raltitrexed, with a yield of 80.6percent, an HPLC purity of 99.8percent,
Reference:
[1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Patent: CN106957296, 2017, A, . Location in patent: Paragraph 0064; 0065
[3] Patent: CN107616976, 2018, A, . Location in patent: Paragraph 0090; 0091
[4] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
2
[ 112889-02-8 ]
[ 112887-68-0 ]
Reference:
[1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[3] Patent: CN106957296, 2017, A,
[4] Patent: CN107616976, 2018, A,
3
[ 106585-63-1 ]
[ 112887-68-0 ]
Reference:
[1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[2] Patent: CN106957296, 2017, A,
[3] Patent: CN106957296, 2017, A,
[4] Patent: CN106957296, 2017, A,
[5] Patent: CN106957296, 2017, A,
[6] Patent: CN107616976, 2018, A,
4
[ 106585-64-2 ]
[ 112887-68-0 ]
Reference:
[1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[2] Patent: CN106957296, 2017, A,
[3] Patent: CN106957296, 2017, A,
[4] Patent: CN106957296, 2017, A,
[5] Patent: CN106957296, 2017, A,
[6] Patent: CN107616976, 2018, A,
5
[ 112888-43-4 ]
[ 112887-68-0 ]
Reference:
[1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
6
[ 132463-33-3 ]
[ 112887-68-0 ]
Reference:
[1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
7
[ 39978-57-9 ]
[ 112887-68-0 ]
Reference:
[1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[2] Patent: CN107616976, 2018, A,
8
[ 1118-89-4 ]
[ 112887-68-0 ]
Reference:
[1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
9
[ 132463-32-2 ]
[ 112887-68-0 ]
Reference:
[1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
10
[ 131052-68-1 ]
[ 112887-68-0 ]
Reference:
[1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
11
[ 16450-41-2 ]
[ 112887-68-0 ]
Reference:
[1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Patent: CN107616976, 2018, A,
To the reaction flask, 1.35 g of sodium hydroxide and 3.3 ml of water were added, and the mixture was cooled to 25 C or lower, and 1.35 g of the starting material (Compound 2) was slowly added with stirring. The mixture was further stirred for 1.5 to 2 hours, and then the reaction solution (2 × 27ml), water phase filtration. The filtrate was stirred with 2M hydrochloric acid to adjust the pH to 3.0, and the mixture was stirred for 2 hours. The product was washed with distilled water and the solid was dried under vacuum at 80 C for 10 hours to give 0.96 g of product, 80% yield and 99.5% HPLC purity.
80.6%
With sodium hydroxide; at 20℃; for 2.0h;
340.0 g of N-[[5-[N-(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)-methyl]-N-methyl]Amino-2-thiophenecarbonyl]-L-glutamic acid diethyl ester was added in portions to a 3N sodium hydroxide solution (6500 ml) and the reaction was stirred at room temperature for 2 hours. TLC monitored the progress of the reaction. After the reaction was completed, the pH was adjusted to 3 to 4 with 3N hydrochloric acid, the crystals were further stirred for 1 hour, and suction filtered to give a yellow solid. Recrystallization from methanol-water (4:1) gave 244.2 g of a pale yellow solid, namely raltitrexed, with a yield of 80.6%, an HPLC purity of 99.8%,
77.6%
With water; sodium hydroxide; at 0 - 15℃; for 2.0h;
109.5 g of a compound of formula VIa (0.213 mol) is added to an aqueous sodium hydroxide solution,0 ~ 15 for 2h,Washed with ethyl acetate, adjusted to pH = 3.6 with hydrochloric acid,Precipitation of a large amount of solids,Continue stirring for 30min, filter,75.8 g of yellow-green solid raltitrexed (compound of formula I) was obtained,The yield was 77.6%.
Specific particularly preferred quinazolines of the invention form the group of compounds: ... N-p-[N-(2-ethyl-3,4-dihydro-4-oxoquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl-L-glutamic acid, N-p-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-o-fluorobenzoyl-L-glutamic acid, N-p-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-ethylamino]-o-fluorobenzoyl-L-glutamic acid, N-p-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-o-fluorobenzoyl-L-glutamic acid, N-{5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl}-L-glutamic acid, N-{5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-ethylamino]-2-thenoyl}-L-glutamic acid, N-{5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino] picolinoyl}-L-glutamic acid, N-p-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-(2-fluoroethyl)amino]benzoly-L-glutamic acid, ...
N - p -[ N -(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)- N -(prop-2-ynyl)amino]- o -fluorobenzoyl-L-glutamic acid; N -{5-[ N -(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)- N -methylamino]-2-thenoyl}-L-glutamic acid, N -{5-[ N -(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)- N -ethylamino]-2-thenoyl}-L-glutamic acid, N -{5-[ N -(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)- N -(prop-2-ynyl)amino[picolinoyl}-L-glutamic acid,
With manganese(IV) oxide; In ethanol; water; at 130℃; for 4.0h;
The 200mg Raltitrexed raw material Placed in500 mL three-necked flask,With 200mL ethanol concentration of 55% ethanol solution dissolved,Adding 50 mg of manganese dioxide powder,Insert the thermometer on a three-necked flask,Agitator and condensing reflux equipment,Placed in the oil bath reaction,When the temperature of the reaction solution rises to 130 C,The reaction was stirred for 4 hours.After the reaction,Cooled to room temperature,The filtrate was collected by filtration,Concentrated and purified by silica gel column chromatography.The eluent was a mixed solvent of dichloromethane-methanol volume ratio of 3: 1,Isocratic elution,The target fractions (about 5-6 column volumes) were collected according to the thin layer panel color monitoring.The desired fractions were concentrated to dryness to give a white powder (162.5mg),The condensed impurities formed by the condensation of two carboxyl groups of raltitrexate were identified.